Company

VALANX Biotech GmbH

Vienna-based biotech developing targeted biologics with a site-specific protein conjugation platform for immunology and oncology.

About

VALANX Biotech GmbH, founded in 2017 in Austria and based in Vienna, develops a site-specific protein conjugation platform for targeted biologics. Its flagship GoldenSite platform is aimed at therapeutic applications in immunology and oncology, and its clients include pharmaceutical and biotechnology companies. In March 2026 the company raised EUR 3 mn in venture funding from Fournier-Majoie Foundation, Fujifilm, Xista Science Ventures, Tecnet Equity, and SOSV. The company is led by Michael Lukesch.

4Funding rounds

4Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in